Lupus Research Alliance News
Results Presented at EULAR Find Investigational Lupus Treatment NKTR-358 Safe

June 13, 2019 New results from a clinical study with healthy volunteers found the investigational compound NKTR-358 safe and well-tolerated, providing support for testing it as a treatment for autoimmune diseases such as lupus. Researchers have known that impaired production of interleukin-2 (IL-2) and dysfunctioning regulatory T cells called Tregs are key to breaking down […] READ MORE

Making Good Immune System Cells Turn Bad

Normally helpful immune system cells become harmful in patients with lupus. With a Novel Research Grant from the LRA, a team led by Dr. Frances Lund of the University of Alabama at Birmingham and Dr. Ignacio Sanz of Emory University in Atlanta and has discovered one possible reason why. The immune cells known as B […] READ MORE

Lupus Counts as a National Men’s Health Issue

June is National Men’s Health Month, when the Lupus Research Alliance works to raise awareness of lupus as a health issue among men to help early diagnosis and treatment.  If a man has symptoms like extreme fatigue, skin rashes, joint pain and unexplained fevers – symptoms that can indicate lupus – he should talk to […] READ MORE

Anti-Nuclear Antibodies May Confuse Lupus Diagnosis

Patients who may have lupus typically undergo an “ANA” test to detect anti-nuclear antibodies (ANAs). Lupus Research Alliance Distinguished Innovator Award recipient Dr. Shu Man Fu of the University of Virginia and colleagues found that people who don’t have lupus also produce ANAs. This suggests that patients can not be diagnosed with lupus just because […] READ MORE

New Study Partly Funded by LRA Reveals Novel Lupus Drug Targets

NEW YORK, NY – May 29. Researchers partly funded by the Lupus Research Alliance (LRA) have found possible new targets for drugs to treat lupus after snapping the first close-up of a molecule that promotes inflammation. The molecule that Target Identification in Lupus (TIL) grant recipient Dr. Roger Greenberg at University of Pennsylvania and Dr. […] READ MORE

Discovering Lupus Heterogeneity

May 22, 2019 Lupus is heterogeneous, meaning that symptoms are many and vary widely from patient to patient — one person may develop a rash, while another may have high blood pressure, joint pain, and anemia. About two thirds of adults with lupus have above-normal levels of immune system molecules called type I interferons that […] READ MORE

LRA Researchers Reveal New Drug Targets at Leading Immunology Conference

May 22, 2019 Data presented by several Lupus Research Alliance-funded scientists at the recent American Association of Immunologists Annual Meeting suggests many  avenues for new lupus treatments. Some scientists presented data posing new targets for drug development, while others have discovered cells that suppress the immune response and could be harnessed as treatments. Reining in […] READ MORE

Celebrate Clinical Trials Day May 20!

May 20, 2019 It’s Clinical Trials Day when the Lupus Research Alliance recognizes all the people we support who advance clinical research – scientists who identify and develop potential ways to diagnose, monitor and treat lupus,  researchers who design and conduct the studies to test these methods, and the volunteers who take part in the […] READ MORE

LRA Board Member Brenda Blackmon Honored by Caribbean Tourism Organization

May 16, 2019 We are proud to share that Brenda Blackmon, an active member of our Board of Directors, was named “Distinguished Friend of the Caribbean” by the Caribbean Tourism Organization. The award will be given at the Caribbean Tourism Industry Awards gala June 6  at the Wyndham New Yorker (481 Eighth Avenue) during Caribbean […] READ MORE

Learn and connect with our community!